Tuesday 13 October 2026 Export ASMB’s income statement to Excel — free account

Assembly Biosciences, Inc.

Assembly Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $72.3 million, up 153.5% from fiscal 2024. In the quarter to June 2026, revenue grew 38.9%, EPS grew 85.0% and free cash flow grew 7.58%, each against the same quarter a year earlier. Revenue growth for three consecutive years.

20.95 1.82 −7.99%

Follow ASMB

Alert me

Market cap: $463.6M
P/E: 22.3×
Fwd P/E: −21.1×
Dividend yield: —
F-score: 4/9
Altman Z: 1.06
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 0.01

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	2	—	—	1	—	—	—	—

Insider Ownership 22.62%

Capital & Financial Ratios $m

Market Cap 463.61

Revenue 74.85

Net Income (0.04)

Free Cash Flow (38.57)

Net Debt (320.36)

Current Ratio 13.99

Debt/Equity 0.00

P/E ratio 22.32

Fwd P/E (21.10)

P/S ratio 5.74

P/B ratio 1.40

Past 5Y EPS Growth —

This Y EPS Growth (10.58%)

Next Y EPS Growth (401.32%)

Next Y revenue growth (12.27%)

Next 5Y EPS Growth 44.88%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 58.39%

10-year low 10-year high

P/B against its own 10 years 38.50%

10-year low 10-year high

EV/Sales against its own 10 years 14.89%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	130	112	248	320
Receivables	0	—	1	1
Inventory	—	—	—	—
Other	—	—	—	—
	134	116	255	328

	2023	2024	2025	Q'26
Payables	0	1	1	1
ST’ Debt	—	—	—	—
Other	—	—	—	—
	39	48	49	23

Compound Annual Growth %

	10y	5y	3y
Sales	—	35.27%	126.12%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	5.70%	(2.99%)	35.74%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	8	13	—	—	—
’25	9	10	11	42	72
’24	6	9	7	7	29
’23	—	—	—	—	7
’21	—	—	6	—	6
’20	4	39	35	1	79
’19	4	3	4	5	16

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(22)	(15)	—	—	—
’25	(23)	(17)	(15)	14	(41)
’24	(18)	(17)	(15)	0	(51)
’23	(23)	(14)	(14)	74	23
’22	(28)	(18)	(20)	(19)	(84)
’21	(33)	(22)	(19)	(19)	(93)
’20	(25)	(23)	11	(25)	(63)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(22)	(15)	—	—	—
’25	(23)	(17)	(15)	14	(41)
’24	(18)	(17)	(15)	0	(51)
’23	(23)	(14)	(14)	74	23
’22	(28)	(18)	(20)	(19)	(85)
’21	(36)	(22)	(19)	(19)	(96)
’20	(25)	(24)	11	(25)	(63)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.54)	(0.20)	—	—	—
’25	(1.17)	(1.33)	(0.72)	2.48	(0.55)
’24	(1.66)	(1.98)	(1.51)	(1.57)	(6.69)
’23	(4.44)	(3.84)	(3.24)	(1.75)	(13.38)
’22	(5.76)	(6.12)	(5.76)	(5.52)	(23.05)
’21	(8.28)	(6.60)	(4.92)	(16.45)	(36.01)
’20	(9.12)	2.28	(1.08)	(13.32)	(21.01)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	51.96	142.20	222.96	97.56	57.36	24.36	9.84	7.68	9.12	7.75	Analyst estimates 2026–2028 Powerpack
	High	174.00	628.44	808.32	308.16	334.08	84.24	29.40	21.36	19.93	39.71
People
People	Employees	69	79	95	115	139	102	68	65	73	73
	Revenue/emp, $m	0.00	0.11	0.16	0.14	0.57	0.06	0.00	0.11	0.39	0.99
Income, $m
Income, $m	Revenue	—	9	15	16	79	6	—	7	29	72
	Gross margin, %	0.00	100.00	100.00	100.00	100.00	100.00	0.00	100.00	100.00	100.00
	EBT	(45)	(52)	(90)	(98)	(62)	(132)	(93)	(61)	(40)	(6)
	EBT margin, %	0.00	(575.00)	(605.59)	(616.48)	(78.57)	(2,116.82)	0.00	(854.32)	(139.72)	(8.47)
	Net income	(44)	(43)	(91)	(98)	(62)	(130)	(93)	(61)	(40)	(6)
	Depreciation	0	0	0	(1)	1	43	1	(1)	(4)	(2)
Per share, $
Per share, $	Revenue	0.00	6.10	7.79	7.30	26.81	1.73	0.00	1.57	4.75	6.45
	Earnings	(30.85)	(28.93)	(47.78)	(44.66)	(21.01)	(36.01)	(23.05)	(13.38)	(6.69)	(0.55)
	Cash flow	(24.31)	1.26	(34.20)	(38.43)	(21.33)	(25.91)	(20.94)	4.97	(8.51)	(3.67)
	Capex	(0.10)	(0.58)	(0.18)	(0.71)	(0.16)	(0.62)	(0.03)	(0.05)	0.00	(0.01)
	Free cash flow	(24.41)	0.67	(34.38)	(39.14)	(21.49)	(26.53)	(20.96)	4.92	(8.52)	(3.67)
	Book value	55.67	76.50	110.91	124.90	81.52	46.86	20.49	8.98	5.56	18.44
	Shares, m	1	1	2	2	3	4	4	5	6	11
Valuation, ×
Valuation, ×	P/E	—	0.00	0.00	0.00	0.00	0.00	—	0.00	0.00	0.00
	P/S	—	91.05	34.83	33.64	2.71	1.24	—	0.56	3.32	5.27
	P/B	—	7.26	2.45	1.97	0.89	0.60	—	1.11	2.84	1.84
	EV/Sales	—	77.75	20.10	16.48	(0.03)	(0.56)	—	(1.04)	(0.61)	1.84
	EV/FCF	—	824.76	(4.56)	(3.07)	0.03	0.48	—	(3.76)	0.34	(3.24)
Cash, $m
Cash, $m	Operating cash flow	(35)	2	(65)	(84)	(63)	(93)	(84)	23	(51)	(41)
	Capex	0	(1)	0	(2)	0	(2)	0	0	0	0
	Free cash flow	(35)	1	(65)	(86)	(63)	(96)	(85)	23	(51)	(41)
Balance, $m
Balance, $m	Working capital	46	110	204	258	200	138	81	95	68	206
	Total debt	—	—	—	12	10	6	3	—	—	—
	Net debt	(53)	(120)	(218)	(274)	(216)	(147)	(92)	(130)	(112)	(248)
	Shareholders’ equity	80	113	211	273	241	169	83	41	33	207
Returns, %
Returns, %	ROA	(38.18)	(32.02)	(41.50)	(32.12)	(19.95)	(54.75)	(63.58)	(51.32)	(31.39)	(3.25)
	ROIC	(105.14)	0.00	0.00	0.00	(167.54)	(371.85)	0.00	0.00	0.00	0.00
	ROE	(44.57)	(44.36)	(56.06)	(40.36)	(24.19)	(63.42)	(74.00)	(98.95)	(107.92)	(5.10)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ARVN Arvinas, Inc.	$499.6M	57.3×	— (loss-making)	+1,014.73% (above 0%: growing)	n/m	+49.79% (above 0%: growing)	96.40%	65.72%	Compare
EPRX Eupraxia Pharmaceuticals Inc.	$491.7M	— (loss-making)	—	—	n/m	−56.41% (below 0%: shrinking)	—	0.00%	Compare
MPLT MapLight Therapeutics, Inc.	$490.7M	— (loss-making)	—	—	n/m	−31.91% (below 0%: shrinking)	—	0.00%	Compare
AUTL Autolus Therapeutics PLC Sponsored ADR	$481.8M	— (loss-making)	— (loss-making)	+118.37% (above 0%: growing)	n/m	+67.55% (above 0%: growing)	55.20%	(95.95%)	Compare
OVID Ovid Therapeutics	$480.4M	— (loss-making)	— (loss-making)	+463.85% (above 0%: growing)	n/m	−268.54% (below 0%: shrinking)	100.00%	(2,141.61%)	Compare
ASMB Assembly Biosciences, Inc.	$479.1M	22.3×	— (loss-making)	+38.94% (above 0%: growing)	n/m	+7.58% (above 0%: growing)	100.00%	(47.44%)
YDES YD Bio Limited	$476.8M	—	—	—	—	—	—	—	Compare
RZLT Rezolute, Inc.	$471.1M	— (loss-making)	—	—	n/m	+40.23% (above 0%: growing)	0.00%	0.00%	Compare
ENTX Entera Bio Ltd.	$462.4M	— (loss-making)	— (loss-making)	+200.00% (above 0%: growing)	n/m	−108.86% (below 0%: shrinking)	0.00%	0.00%	Compare
Median of peers	$481.1M	—	—	+331.93%	—	−31.91%	55.20%	0.00%

All 614 Biotechnology stocks →

Assembly Biosciences, Inc. (ASMB) key facts

Strength: Assembly Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $72.3 million, up 153.5% from fiscal 2024.
Assembly Biosciences, Inc. (ASMB) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 13, 2026, ASMB traded at $20.95, a market capitalization of $463.6 million.
Return on equity was −5.10% and debt-to-equity 0.00.
Its Piotroski F-score is 4 out of 9 and its Altman Z-score is 1.06 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.